 |
|
Response of Oral Lichen Planus to Topical Tacrolimus in 37 Patients
Julie A. Byrd, MD;
Mark D. P. Davis, MD;
Alison J. Bruce, MD;
Lisa A. Drage, MD;
Roy S. Rogers III, MD
Arch Dermatol. 2004;140:1508-1512.
ABSTRACT
| |
Background Topical tacrolimus has been reported to be effective for the treatment of oral lichen planus. This article describes our experience with topical tacrolimus in patients treated for symptomatic oral lichen planus.
Observations A survey was mailed to 40 patients with symptomatic oral lichen planus treated with topical tacrolimus. Surveys were completed by 37 patients (93%) a mean of 1.3 years after initiation of treatment. Thirty-three (89%) of the 37 patients reported symptomatic improvement, and 31 (84%) reported partial to complete lesion clearance while using topical tacrolimus. On average, patients noted improvement in 1 month. Twelve patients (32%) reported adverse effects consistent with those reported previously (ie, burning, irritation, and tingling). Among the 28 patients still using the medication, 15 patients (54%) apply it at least once daily. Of the 9 patients who discontinued using the medication, 5 experienced recurrence.
Conclusions Topical tacrolimus is effective for the treatment of oral lichen planus. Most patients experienced symptomatic improvement in less than 1 month. However, the effect is temporary; when topical tacrolimus is discontinued, oral lichen planus may flare again.
INTRODUCTION
Symptomatic oral lichen planus (OLP) may be recalcitrant to treatment and disabling. In addition to oral involvement, mucosal areas such as the genitalia, ear canal, and esophagus may be affected. When lichen planus involves other mucosal surfaces, it may be more resistant to treatment.1-6
Multiple topical and systemic treatments for OLP have been reported to be effective, including topical and systemic corticosteroids, griseofulvin, hydroxychloroquine, dapsone, topical retinoids, and topical cyclosporine.7-20 However, in some patients, OLP is resistant to these treatments, or patients are unable to tolerate a treatment because of its adverse effects.
Topical tacrolimus has been reported to be effective for OLP, including those forms that had been recalcitrant to treatment21-26 (Table 1). Many of those reports are of few patients, however, and follow-up was relatively short. We report the experience of our patients with OLP, both erosive and reticulated, with topical tacrolimus and their response to treatment over a longer period. This is a larger group, which does not include the 13 patients on whom we reported in 2002.23
|
|
|
|
Table 1. Review of Studies of Symptomatic Oral Lichen Planus (OLP) Treated With Topical Tacrolimus
|
|
|
METHODS
Forty patients who had been prescribed treatment with topical tacrolimus for OLP were identified; all had been seen in the Department of Dermatology at Mayo Clinic, Rochester, Minn, from February 2000 to August 2002.
Demographic information was obtained from a retrospective review of the medical records. The institutional review board of Mayo Foundation approved the study. A follow-up survey was mailed to the patients by the Survey Research Center. The survey was used to obtain information regarding symptomatic and lesional response to topical tacrolimus treatment, time to improvement, current use, and adverse effects, if any. In addition, clinical findings after use of topical tacrolimus were retrospectively reviewed.
Inclusion criteria consisted of the following: (1) clinical evidence of OLP, as shown by reticulated erythematous or erosive lesions involving the oral mucosa or histopathologic changes consistent with lichenoid mucositis, with or without supportive direct immunofluorescence testing (cytoid bodies with  1 of the following: IgG, IgM, IgA, C3, or shaggy deposition of fibrinogen along the basement membrane zone27-28); (2) symptoms of pain, irritation, or both; and (3) prescription and use of topical tacrolimus.
Patients who responded that their symptoms were somewhat better or much better were considered to have symptomatic improvement. Response was defined as reports that lesions were almost gone or completely gone.
RESULTS
Forty patients with symptomatic OLP who had been prescribed topical tacrolimus (twice-daily applications to the affected areas) were mailed a survey. Thirty-nine (98%) of the 40 patients responded that they were using the medication, and 1 patient responded that he did not fill the prescription. Two patients wrote a comment on the survey and did not complete the questionnaire. One responded that topical tacrolimus made her tongue feel as if it had been burned, and the other responded that he had difficulty getting the medication to stay on his cheeks. Our results are from the remaining 37 patients (93%) who used the medication and responded to the survey.
Because the commercial form of topical tacrolimus was not yet available, some patients were initially prescribed a formulation of tacrolimus mixed with a petrolatum ointment (Aquaphor; Beiersdorf, South Norwalk, Conn) to make 0.03% and 0.1% concentrations. Fourteen patients (38%) initially received the 0.03% concentration and 1 patient (2%) the 0.1% concentration in petrolatum, but the commercial product was prescribed for all patients when it became available. Twenty-two patients were initially prescribed commercially prepared topical tacrolimus, 18 patients (49%) the 0.03% concentration, and 4 patients (11%) the 0.1% concentration.
Patient demographics and clinical characteristics are summarized in Table 2. The mean age of the 32 women and 5 men was 64 years (range, 38-82 years). Twenty-three (62%) of the 37 patients had predominantly reticulated lichen planus, and 14 (38%) had predominantly erosive lichen planus. All patients had OLP, some at more than 1 site. Concomitant genital involvement was present in 11 patients (30%) and cutaneous involvement in 3 patients (8%). Two (5%) had otic involvement, and 1 (3%) had esophageal lichen planus. Twenty-five patients (68%) had histopathologic confirmation of lichen planus, and 11 (30%) had supportive results from direct immunofluorescence studies.
|
|
|
|
Table 2. Demographics of Patients With Oral Lichen Planus Using Topical Tacrolimus
|
|
|
The mean duration of OLP before starting topical tacrolimus treatment was 4.4 years. Prior treatment had been unsuccessful in nearly all patients (35 of 37). In the 2 remaining patients, topical tacrolimus was first-line therapy. One patient continues to take hydroxychloroquine, 1 patient continues to take oral corticosteroids, and 3 patients continue to use topical antifungals intermittently.
The responses to the survey are summarized in Table 3. Surveys were completed a mean of 1.3 years after initiation of topical tacrolimus treatment (range, 49 days to 2.7 years). Thirty-one patients (84%) reported that they were somewhat or very satisfied with topical tacrolimus treatment and that they would recommend the medication to others.
|
|
|
|
Table 3. Patient Response to Treatment of Oral Lichen Planus With Topical Tacrolimus
|
|
|
On average, patients used topical tacrolimus for 1.1 years (range, 5 days to 2.7 years) and reported an improvement within 1 month (range, 3 days to 6 months). Thirty-four patients (92%) reported that they used the medication as instructed all the time or most of the time. Symptomatic improvement was reported by 33 patients (89%). Thirty-one patients (84%) reported partial to complete lesion clearance with topical tacrolimus treatment (Figure). One patient reported that the lesions increased, and 1 reported that the symptoms were much worse.
|
|
|
|
Figure. Response of gingival lichen planus to tacrolimus treatment. A, Gingival lichen planus with characteristic erythema and Wickham striae; B, resolution of lichen planus after 7 weeks of treatment with tacrolimus ointment.
|
|
|
Clinical findings after topical tacrolimus use were available for 24 of the 37 patients. Of these 24 patients, 5 did not have a follow-up visit until 1 year or more after starting topical tacrolimus treatment because of traveling constraints; of these 5 patients, 2 had clinical improvement and 3 had resolution of their OLP lesions. The remaining 19 patients were seen a mean of 2 months after initiation of topical tacrolimus treatment; of these, 12 had clinical improvement and 7 had resolution of their OLP lesions.
Twenty-five patients (68%) reported no difficulties, and 12 patients (32%) reported experiencing problems with using the medication. Of these 12 patients, 4 (11%) reported that the medicine caused irritation; 5 (14%), that it caused burning; and 3 (8%), that it caused tingling. Two patients (17%) also reported an objectionable taste. Four patients each reported other problems: bad breath, extra phlegm in the mouth, swelling of the mouth and lips, and teeth problems.
Twenty-eight patients (76%) continue to use topical tacrolimus. The mean follow-up of the patients still using topical tacrolimus is 1.3 years (range, 49-968 days). Fifteen (54%) of these 28 patients apply the medication more than once daily. The remaining 13 patients use topical tacrolimus twice weekly or less.
Of the 9 patients (24%) not currently using topical tacrolimus, 5 reported that they discontinued the medicine because of adverse effects, 1 because she did not notice any change in the lichen planus, and 2 because the lichen planus was better. These patients applied the medication for an average of 4.9 months (range, 5 days to 1.3 years). After stopping treatment with topical tacrolimus, 5 patients (56%) reported that the lichen planus returned, and 3 (33%) reported that it stayed the same. The remaining patient did not answer this question.
COMMENT
Topical tacrolimus treatment was safe and effective in most patients, 89% of whom experienced symptomatic response and 84% of whom reported lesion clearance. Lesions responded to treatment within 6 months (mean, 1 month).
The demographic characteristics of our patients were similar to those of patients previously reported. Our patients had both erosive and reticulated OLP, whereas most prior reports focused on erosive OLP alone. Treatment with topical tacrolimus appears to be effective for both erosive and reticulated forms of OLP.
Also, 30% of our patients had genital involvement associated with OLP, and 8% had either otic or esophageal involvement. It has been reported that patients with OLP associated with genital lichen planus (the vulvovaginal gingival syndrome) typically are more difficult to treat than those with other forms of lichen planus.1-6 All 11 patients with both oral and genital lesions had symptomatic improvement in both areas. These data are discussed further in another article.29 The 2 patients with otic involvement also had improvement in their otic lichen planus with a topical tacrolimus suspension.
Topical tacrolimus treatment was effective as first-line therapy in 2 patients. Thirty-one patients whose OLP was recalcitrant to other therapies reported topical tacrolimus to be effective. Two patients who responded to the questionnaire continued systemic treatment, one with hydroxychloroquine and the other with corticosteroids; in both patients, OLP improved markedly with the addition of topical tacrolimus. Symptoms were unchanged in 3 patients, and 1 patient reported that symptoms and lesions worsened while using topical tacrolimus.
Adverse effects were reported by one third of patients, and they were similar to those previously reported (irritation, burning, and/or tingling). Only 5 patients discontinued use of topical tacrolimus because of adverse effects; in the remaining patients, adverse effects resolved with continued use.
Most of our patients continue to use topical tacrolimus. Although topical tacrolimus is effective at controlling disease, we found that it rarely seems to result in complete remission of OLP. This is consistent with observations from prior studies.21-26 Long-term use (>1 year) did not result in any serious adverse effects in our patients, most of whom were satisfied with topical tacrolimus treatment.
This is a retrospective study with a patient survey and therefore is subject to patient recall bias. However, the mailed survey was the most effective way to follow up with our patients, who often live a great distance from our clinic. The survey offered a standardized, objective way to obtain our data, and the patients who were able to return for follow-up had clinical findings that correlated with the survey results.
In summary, we followed up 37 patients with symptomatic OLP by means of a mailed questionnaire. Most of these patients responded to topical tacrolimus treatment with both clinical and symptomatic improvement. The effect of topical tacrolimus usually occurred within 1 month of treatment; however, most patients require maintenance therapy. No serious adverse effects of topical tacrolimus were noted after more than 1 year of follow-up, which supports the thesis that topical tacrolimus is a safe and effective treatment for OLP.
AUTHOR INFORMATION
Correspondence: Mark D. P. Davis, MD, Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.
Accepted for Publication: June 7, 2004.
Financial Disclosure: None.
Author Affiliations: Department of Dermatology, Mayo Clinic, Rochester, Minn.
REFERENCES
| |
1. Pelisse M, Leibowitch M, Sedel D, Hewitt J. A new vulvovaginogingival syndrome: plurimucous erosive lichen planus [in French]. Ann Dermatol Venereol. 1982;109:797-798.
ISI
| PUBMED
2. Pelisse M. The vulvo-vaginal-gingival syndrome: a new form of erosive lichen planus. Int J Dermatol. 1989;28:381-384.
ISI
| PUBMED
3. Eisen D. The vulvovaginal-gingival syndrome of lichen planus: the clinical characteristics of 22 patients. Arch Dermatol. 1994;130:1379-1382.
ABSTRACT
4. Rogers RS III. Erosive orogenital lichen planus in women (vulvovaginal-gingival syndrome) [abstract]. J Oral Pathol Med. 1998;27:362.
5. Eisen D. The evaluation of cutaneous, genital, scalp, nail, esophageal, and ocular involvement in patients with oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88:431-436.
FULL TEXT
|
ISI
| PUBMED
6. Rogers RS III, Eisen D. Erosive oral lichen planus with genital lesions: the vulvovaginal-gingival syndrome and the peno-gingival syndrome. Dermatol Clin. 2003;21:91-98.
FULL TEXT
|
ISI
| PUBMED
7. Edwards PC, Kelsch R. Oral lichen planus: clinical presentation and management. J Can Dent Assoc. 2002;68:494-499.
8. Voute AB, Schulten EA, Langendijk PN, Kostense PJ, van der Waal I. Fluocinonide in an adhesive base for treatment of oral lichen planus: a double-blind, placebo-controlled clinical study. Oral Surg Oral Med Oral Pathol. 1993;75:181-185.
FULL TEXT
|
ISI
| PUBMED
9. Boisnic S, Branchet MC, Pascal F, Ben Slama L, Rostin M, Szpirglas H. Topical tretinoin in the treatment of lichen planus and leukoplakia of the mouth mucosa: a clinical evaluation [in French]. Ann Dermatol Venereol. 1994;121:459-463.
ISI
| PUBMED
10. Sieg P, Von Domarus H, Von Zitzewitz V, Iven H, Farber L. Topical cyclosporin in oral lichen planus: a controlled, randomized, prospective trial. Br J Dermatol. 1995;132:790-794.
ISI
| PUBMED
11. Frances C, Boisnic S, Etienne S, Szpirglas H. Effect of the local application of ciclosporine A on chronic erosive lichen planus of the oral cavity. Dermatologica. 1988;177:194-195.
ISI
| PUBMED
12. Eisen D, Ellis CN, Duell EA, Griffiths CE, Voorhees JJ. Effect of topical cyclosporine rinse on oral lichen planus: a double-blind analysis. N Engl J Med. 1990;323:290-294.
ABSTRACT
13. Becherel PA, Chosidow O, Boisnic S, et al. Topical cyclosporine in the treatment of oral and vulvar erosive lichen planus: a blood level monitoring study. Arch Dermatol. 1995;131:495-496.
FULL TEXT
|
ISI
| PUBMED
14. Eisen D, Griffiths CE, Ellis CN, Nickoloff BJ, Voorhees JJ. Cyclosporin wash for oral lichen planus [letter]. Lancet. 1990;335:535-536.
ISI
| PUBMED
15. Hersle K, Mobacken H, Sloberg K, Thilander H. Severe oral lichen planus: treatment with an aromatic retinoid (etretinate). Br J Dermatol. 1982;106:77-80.
FULL TEXT
|
ISI
| PUBMED
16. Sehgal VN, Abraham GJ, Malik GB. Griseofulvin therapy in lichen planus: a double-blind controlled trial. Br J Dermatol. 1972;87:383-385.
FULL TEXT
|
ISI
| PUBMED
17. Eisen D. Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: an open trial. J Am Acad Dermatol. 1993;28:609-612.
ISI
| PUBMED
18. Kumar B, Kaur I, Bhattacharya M. Dapsone in lichen planus [letter]. Acta Derm Venereol. 1994;74:334.
ISI
| PUBMED
19. Setterfield JF, Black MM, Challacombe SJ. The management of oral lichen planus. Clin Exp Dermatol. 2000;25:176-182.
FULL TEXT
|
ISI
| PUBMED
20. Cribier B, Frances C, Chosidow O. Treatment of lichen planus: an evidence-based medicine analysis of efficacy. Arch Dermatol. 1998;134:1521-1530.
FREE FULL TEXT
21. Vente C, Reich K, Rupprecht R, Neumann C. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol. 1999;140:338-342.
FULL TEXT
|
ISI
| PUBMED
22. Lener EV, Brieva J, Schachter M, West LE, West DP, el-Azhary RA. Successful treatment of erosive lichen planus with topical tacrolimus. Arch Dermatol. 2001;137:419-422.
FREE FULL TEXT
23. Rozycki TW, Rogers RS III, Pittelkow MR, et al. Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J Am Acad Dermatol. 2002;46:27-34.
FULL TEXT
|
ISI
| PUBMED
24. Kaliakatsou F, Hodgson TA, Lewsey JD, Hegarty AM, Murphy AG, Porter SR. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol. 2002;46:35-41.
FULL TEXT
|
ISI
| PUBMED
25. Morrison L, Kratochvil FJ III, Gorman A. An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol. 2002;47:617-620.
FULL TEXT
|
ISI
| PUBMED
26. Olivier V, Lacour JP, Mousnier A, Garraffo R, Monteil RA, Ortonne JP. Treatment of chronic erosive oral lichen planus with low concentrations of topical tacrolimus: an open prospective study. Arch Dermatol. 2002;138:1335-1338.
FREE FULL TEXT
27. Weedon D. Skin Pathology London, England: Churchill Livingstone; 2002:31-37.
28. Helander SD, Rogers RS III. The sensitivity and specificity of direct immunofluorescence testing in disorders of mucous membranes. J Am Acad Dermatol. 1994;30:65-75.
ISI
| PUBMED
29. Byrd JA, Davis MDP, Rogers RS III. Recalcitrant symptomatic vulvar lichen planus: response to topical tacrolimus. Arch Dermatol. 2004;140:715-720.
FREE FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Treatment of Oral Erosive Lichen Planus With 1% Pimecrolimus Cream: A Double-blind, Randomized, Prospective Trial With Measurement of Pimecrolimus Levels in the Blood
Passeron et al.
Arch Dermatol 2007;143:472-476.
ABSTRACT
| FULL TEXT
New and Old Therapeutics for Oral Ulcerations
Bruce and Rogers
Arch Dermatol 2007;143:519-523.
FULL TEXT
|
